April is Oral Cancer Month
Links shared publicly online about this topic.
- 406total visits
April is Oral Cancer Month
View full resource at std.about.com
Tags: STD, Cancer, Scientist, Science
Most Recently Shared on March 28, 2011 at 4:40 pm By:
April is Oral Cancer Month: Scientists estimate that approximately thirty-five thousand people will be diag... http://bit.ly/hEF5nw #std
Tremelimumab Shows Promise in Treatment of Liver Cancer
aacr.org — “Tumor burden reduction and disease stabilization occurred in some cases. Tremelimumab also reduced blood levels of hepatitis C virus. CHICAGO — Tremelimumab treatment stabilized patients with advanced hepatocellular carcinoma due to chronic hepatitis C infection for more than 12 months, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.Researchers evaluated 21 patients treated with tremelimumab intravenously at a dose of 15 mg/kg every 90 days for ab” View full resource at aacr.org
Most Recently Shared on April 3, 2012 at 12:29 am By:
Dr. P. D Tapp PhD, Doctor, and Health Executive
Tremelimumab Shows Promise in Treatment of Liver Cancer: http://t.co/tATE1IqK
The Cancer Institute of New Jersey Highlights Prevention, Treatment and Research During National Cancer Control Month
newswise.com — “April marks National Cancer Control Month, which focuses on the importance of prevention, treatment and research in the fight against cancer. The Cancer Institute of New Jersey is making experts available to discuss varied topics relating to these areas, including a vaccine strategy for pancreatic cancer, which aims to harness the body’s own immune system through direct tumor injection; a comprehensive overview of genetic testing and counseling; the benefits of early detection through cancer scr” View full resource at newswise.com
Most Recently Shared on March 29, 2012 at 1:46 pm By:
#health news: The Cancer Institute of New Jersey Highlights Prevention, Treatment and Research During National C... http://t.co/M6HMPD8o
The Cancer Institute of New Jersey Highlights Prevention, Treatment and Research During National Cancer Control Month
newswise.com — “April marks National Cancer Control Month, which focuses on the importance of prevention, treatment and research in the fight against cancer. The Cancer Institute of New Jersey is making experts available to discuss varied topics relating to these areas, including a vaccine strategy for pancreatic cancer, which aims to harness the body’s own immune system through direct tumor injection; a comprehensive overview of genetic testing and counseling; the benefits of early detection through cancer scr” View full resource at newswise.com
Most Recently Shared on March 29, 2012 at 1:42 pm By:
The Cancer Institute of New Jersey Highlights Prevention, Treatment and Research During National Cancer ... http://t.co/6vC0oKFZ #cancer
The Cancer Institute of New Jersey Highlights Prevention, Treatment and Research During National Cancer Control Month
newswise.com — “April marks National Cancer Control Month, which focuses on the importance of prevention, treatment and research in the fight against cancer. The Cancer Institute of New Jersey is making experts available to discuss varied topics relating to these areas, including a vaccine strategy for pancreatic cancer, which aims to harness the body’s own immune system through direct tumor injection; a comprehensive overview of genetic testing and counseling; the benefits of early detection through cancer scr” View full resource at newswise.com
Most Recently Shared on March 29, 2012 at 1:31 pm By:
newswise Health Communicator and Health News
The Cancer Institute of New Jersey Highlights Prevention, Treatment and Research During National Cancer Control Month http://t.co/j8Rkq5rU
Oral Cancer Awareness
fightoralcancer.org — “With Oral Cancer Awareness month just around the corner, we wanted to post a link to a great article about the importance of early intervention in Oral Cancer Prevention and treatment.” View full resource at fightoralcancer.org
Most Recently Shared on March 23, 2012 at 7:49 pm By:
Int'l OC Association Health Organization
Oral Cancer Awareness - http://t.co/iAk7j2Eg
Maura L. Gillison, M.D., Ph.D., Receives AACR’s Richard and Hinda Rosenthal Memorial Award | Oral Cancer News
oralcancernews.org — “Maura L. Gillison, M.D., Ph.D., Receives AACR’s Richard and Hinda Rosenthal Memorial Award | Oral Cancer News” View full resource at oralcancernews.org
Most Recently Shared on March 23, 2012 at 12:31 pm By:
Chillicothe, OH Inaugural Oral Cancer Awareness Walk | Facebook
facebook.com — “Facebook is a social utility that connects people with friends and others who work, study and live around them. People use Facebook to keep up with friends, upload an unlimited number of photos, post links and videos, and learn more about the people they meet.” View full resource at facebook.com
Most Recently Shared on March 20, 2012 at 8:07 pm By:
The Oral Cancer Foundation Health Organization
Come to "Chillicothe, OH Inaugural Oral Cancer Awareness Walk" Saturday, April 28 from 9:00 am to 12:00 pm.... http://t.co/I5YrQYE2
Vemurafenib Extends Survival To 16 Months For Some Patients With Metastatic Melanoma
medicalnewstoday.com — “An international team of researchers from the United States and Australia, including researchers at Moffitt Cancer Center in Tampa, Fla., have found that the oral BRAF inhibitor vemurafenib (PLX40” View full resource at medicalnewstoday.com
Most Recently Shared on March 20, 2012 at 7:05 am By:
Vemurafenib Extends Survival To 16 Months For Some Patients With Metastatic Melanoma http://t.co/4ADvhzXF #skincancer #melanoma
Oral BRAF inhibitor can extend survival to 16 months for patients with MM
news-medical.net — “An international team of researchers from the United States and Australia, including researchers at Moffitt Cancer Center in Tampa, Fla., have found that the oral BRAF inhibitor vemurafenib (PLX4032) when tested in a phase II clinical trial offered a high rate of response in patients with previously treated metastatic melanoma and who had the BRAF mutation.” View full resource at news-medical.net
Most Recently Shared on March 17, 2012 at 9:26 am By:
Oral BRAF inhibitor can extend survival to 16 months for patients with MM: An international team of researchers ... http://t.co/tM2N1Vwa
Taking a pill to fight cancer? Avoid these dangerous drug interactions - Daily Dose: A Boston Globe blog with health news, advice, and information.
boston.com — “Cancer treatments nowadays include not just radiation, surgery, and infusion chemotherapy treatments, but also pills that patients take every day for weeks, months, or even years. Many of these pills, however, interact with common medications such as acid blockers and antihistamines, rendering the cancer drugs less effective or dangerously potent. The majority of cancer patients taking a particular kind of oral cancer drug, known as kinase inhibitors, were taking other medications that interacte” View full resource at boston.com
Most Recently Shared on March 16, 2012 at 10:21 pm By:
Richard G. Lanzara Health Professional
Taking a pill to fight cancer? Avoid these dangerous drug interactions http://t.co/AWzTxPDn #healthcare #medicine #cancer
Response Rate High for Some Patients with Metastatic Melanoma Treated with Vemurafenib
newswise.com — “An international team of researchers from the United States and Australia, including researchers at Moffitt Cancer Center, have found that the oral BRAF inhibitor vemurafenib (PLX4032) when tested in a phase II clinical trial offered a high rate of response in patients with previously treated metastatic melanoma and who had the BRAF mutation. More than 50 percent of the patients in the trial had positive, prolonged responses and a median survival of almost 16 months.” View full resource at newswise.com
Most Recently Shared on March 16, 2012 at 4:47 pm By:
#health news: Response Rate High for Some Patients with Metastatic Melanoma Treated with Vemurafenib http://t.co/NOOLgphV
Response Rate High for Some Patients with Metastatic Melanoma Treated with Vemurafenib
newswise.com — “An international team of researchers from the United States and Australia, including researchers at Moffitt Cancer Center, have found that the oral BRAF inhibitor vemurafenib (PLX4032) when tested in a phase II clinical trial offered a high rate of response in patients with previously treated metastatic melanoma and who had the BRAF mutation. More than 50 percent of the patients in the trial had positive, prolonged responses and a median survival of almost 16 months.” View full resource at newswise.com
Most Recently Shared on March 16, 2012 at 4:42 pm By:
newswise Health Communicator and Health News
Response Rate High for Some Patients with Metastatic Melanoma Treated with Vemurafenib http://t.co/J4PYO8lL
Studies underscore genetic complexity of head and neck squamous cell cancers | Oral Cancer News
oralcancernews.org — “Studies underscore genetic complexity of head and neck squamous cell cancers | Oral Cancer News” View full resource at oralcancernews.org
Most Recently Shared on March 15, 2012 at 3:57 pm By:
Velscope Oral Cancer Detection - YouTube
youtube.com — “Support Oral Cancer Awareness Month this April!” View full resource at youtube.com
Most Recently Shared on March 7, 2012 at 7:40 pm By:
The Oral Cancer Foundation Health Organization
Calling all Dental Offices...Get on board with OCF and register your practice to offer free screenings in honor... http://t.co/5fjhQqvw
AGD - AGDWEBSITELINK01About the AGD - Newsroom - News Releases
agd.org — “News Releases” View full resource at agd.org
Most Recently Shared on February 13, 2012 at 8:47 pm By:
Academy General Dent Health Organization and Dentistry
Happy Anniversary to the AGD! The AGD celebrates 60 years in 2012. Read more about the AGD's history & core values: http://t.co/Z8Zkkv4l
Advertisement
